Merck & Co.

Originally a subsidiary of the German Merck KGaA, the American company became a fully independent entity following World War I. For the next century, it built a vast, diversified portfolio of pharmaceuticals and animal health products. It became a quintessentially stable, "blue-chip" American corporation known for its deep research bench and massive distribution reach, but as it grew older, it struggled to maintain the high-growth innovation rates that Wall Street demanded.

Merck took a massive, multi-billion-dollar risk on a new class of cancer therapies called immune checkpoint inhibitors. The company’s drug, Keytruda, was designed to "take the brakes off" the immune system, allowing it to recognize and destroy cancer cells. When clinical trials proved its effectiveness across a wide range of cancers, Keytruda became a blockbuster. It transformed from a single research project into the most important, high-revenue oncology asset on the planet.

As Keytruda generated record-breaking annual revenues, Merck faced a new, looming existential crisis: the drug was eventually going to lose patent protection, creating a massive "revenue hole." The company spent heavily, using its Keytruda profits to buy up smaller biotech companies and research teams. The goal was to build a diversified pipeline that could eventually replace the colossal revenue stream of its single, flagship cancer-killing molecule.

To diversify its risks, Merck initiated an aggressive expansion into cardiovascular and respiratory therapeutics. By acquiring companies with deep experience in specialized, high-margin disease treatments, Merck worked to prove it wasn't just an "oncology company." The strategy was to leverage its massive, global sales force to push new cardiovascular drugs into the same hospitals where they were already successfully selling Keytruda.

By mid-2026, Merck remains a titan of the global pharmaceutical industry. Under its current leadership, the company has successfully begun to transition away from its extreme dependency on Keytruda. By building a balanced, wide-reaching portfolio of high-value oncology and chronic disease treatments, Merck has successfully stabilized its long-term financial future as a pillar of global healthcare.